Medicus Pharma (MDCX) News Today $2.32 -0.09 (-3.73%) As of 09:32 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDCX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Medicus Pharma Appoints Carolyn Bonner as Acting CFOSeptember 12 at 5:30 PM | tipranks.comMedicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development PipelineSeptember 11, 2025 | tipranks.comMedicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development PipelineSeptember 11, 2025 | theglobeandmail.comMedicus Pharma Ltd. Advances Clinical Trials for Skin Cancer TreatmentSeptember 10, 2025 | tipranks.comMedicus Pharma says UAE SKNJCT-004 Phase 2 trial commences patient recruitmentSeptember 9, 2025 | msn.comMedicus Pharma Ltd. Advances Clinical Trials for Skin Cancer TreatmentSeptember 8, 2025 | tipranks.comMedicus Pharma begins Phase 2 clinical study in UAE to treat BCCSeptember 8, 2025 | proactiveinvestors.comMedicus Pharma Ltd. (NASDAQ: MDCX) Builds Momentum With Antev Acquisition and Pipeline ProgressSeptember 5, 2025 | theglobeandmail.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalSeptember 4, 2025 | americanbankingnews.comMedicus Pharma closes Antev acquisition; sees $6B market potentialSeptember 2, 2025 | proactiveinvestors.comMedicus Pharma nears FDA milestone in cancer trial - ICYMIAugust 30, 2025 | proactiveinvestors.comMedicus Pharma Completes Equity Sales to YorkvilleAugust 22, 2025 | msn.comMedicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of ...August 21, 2025 | finance.yahoo.comMedicus Pharma Advances D-MNA Clinical Program and Expands Strategic PartnershipsAugust 21, 2025 | tipranks.comBiotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)August 20, 2025 | theglobeandmail.comBiotech’s Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)August 19, 2025 | theglobeandmail.comMedicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion MoveAugust 7, 2025 | theglobeandmail.comMedicus Pharma Seeks FDA Fast-Track Approval for Innovative Skin Cancer TreatmentAugust 7, 2025 | theglobeandmail.comMedicus Pharma and HelixNano agree outline deal to develop heat-stable vaccinesAugust 4, 2025 | proactiveinvestors.comMedicus Pharma Appoints Deloitte for Licensing DealJuly 30, 2025 | tipranks.comMedicus Pharma Ltd. Strengthens Board with New AppointmentsJuly 23, 2025 | tipranks.comMedicus Pharma Ltd. Announces Submission of Type C Meeting Request to ...July 23, 2025 | finanznachrichten.deMedicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive ...July 23, 2025 | finanznachrichten.deMedicus Pharma Ltd. Expands Clinical Trials and Announces Strategic AcquisitionJuly 21, 2025 | tipranks.comMedicus Pharma Ltd. (NASDAQ:MDCX): Novel Pipeline Presents Unique Opportunity To Capitalize On Rare Disease Market Worth Over $15 BillionJuly 16, 2025 | theglobeandmail.comMEDICUS PHARMA LTD - FinanzNachrichten.deJuly 16, 2025 | finanznachrichten.deMedicus Pharma Enters Warrant Inducement AgreementJuly 14, 2025 | tipranks.comMedicus Pharma submits Type C meeting request to FDA to advance skin cancer treatmentJuly 8, 2025 | proactiveinvestors.comMedicus Pharma expands pipeline with Antev acquisition - ICYMIJuly 5, 2025 | proactiveinvestors.comMedicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer TreatmentJuly 4, 2025 | seekingalpha.comMedicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - Seeking AlphaJuly 2, 2025 | seekingalpha.comMedicus to acquire UK biotech Antev in share deal worth up to $65mJune 30, 2025 | proactiveinvestors.comMedicus Pharma appoints Andrew Smith as chief operating officerJune 24, 2025 | uk.investing.comMedicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studiesJune 23, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma targets horse cancer with new trial – ICYMIJune 13, 2025 | proactiveinvestors.comMedicus Pharma to Present at Bio Convention and Expand Cancer Treatment PortfolioJune 12, 2025 | tipranks.comMedicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horsesJune 9, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug ...June 9, 2025 | gurufocus.comMedicus Pharma Submits FDA Plan for Novel Equine Cancer TreatmentJune 9, 2025 | tipranks.comMedicus Pharma appoints KPMG as new auditor, expands global clinical programsJune 6, 2025 | proactiveinvestors.comMedicus Pharma completes $7 million public offeringJune 4, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street ZenMay 31, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)May 30, 2025 | marketbeat.comMedicus Pharma unveils pricing of $7M public offeringMay 30, 2025 | proactiveinvestors.comMedicus Pharma prices $7 million share offeringMay 30, 2025 | msn.comMedicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock NewsMay 29, 2025 | gurufocus.comMedicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment TrialsMay 29, 2025 | tipranks.comMDCX Medicus Pharma Ltd.May 29, 2025 | seekingalpha.comMedicus Pharma begins UAE cancer trial expansion – ICYMIMay 25, 2025 | proactiveinvestors.com Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDCX Media Mentions By Week MDCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDCX News Sentiment▼-0.050.94▲Average Medical News Sentiment MDCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDCX Articles This Week▼82▲MDCX Articles Average Week Get the Latest News and Ratings for MDCX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Medicus Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Avalo Therapeutics News MEI Pharma News Forte Biosciences News Cabaletta Bio News Cardiff Oncology News Alpha Cognition News Zura Bio News Scilex News Genelux News TuHURA Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDCX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
